Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- AGIO
- Price
- 27.82
- Stock movement up
- +0.26 (0.94%)
- Company name
- Agios Pharm
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.63B
- Ent value
- 1.65B
- Price/Sales
- 30.20
- Price/Book
- 1.37
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 8.46%
- 1 year return (CAGR)
- -12.91%
- 3 year return (CAGR)
- 5.76%
- 5 year return (CAGR)
- -10.43%
- 10 year return (CAGR)
- -4.54%
Last updated: 2026-03-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
AGIO does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 30.20 |
| Price to Book | 1.37 |
| EV to Sales | 30.48 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 58.59M |
| EPS (TTM) | -7.07 |
| FCF per share (TTM) | -6.47 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 54.03M |
| Gross profit (TTM) | 47.68M |
| Operating income (TTM) | -472.13M |
| Net income (TTM) | -412.78M |
| EPS (TTM) | -7.07 |
| EPS (1y forward) | -5.17 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 88.26% |
| Operating margin (TTM) | -873.87% |
| Profit margin (TTM) | -764.01% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 89.13M |
| Net receivables | 10.58M |
| Total current assets | 942.05M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 101.34M |
| Total assets | 1.30B |
| Accounts payable | 18.36M |
| Short/Current long term debt | 40.21M |
| Total current liabilities | 82.21M |
| Total liabilities | 104.11M |
| Shareholder's equity | 1.19B |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -372.98M |
| Capital expenditures (TTM) | 4.32M |
| Free cash flow (TTM) | -377.29M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -34.60% |
| Return on Assets | -31.82% |
| Return on Invested Capital | -34.07% |
| Cash Return on Invested Capital | -31.14% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 27.76 |
| Daily high | 28.19 |
| Daily low | 27.26 |
| Daily Volume | 510K |
| All-time high | 135.01 |
| 1y analyst estimate | 38.88 |
| Beta | 0.88 |
| EPS (TTM) | -7.07 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| AGIO | S&P500 | |
| Current price drop from All-time high | -79.39% | -1.82% |
| Highest price drop | -87.36% | -56.47% |
| Date of highest drop | 14 Jun 2022 | 9 Mar 2009 |
| Avg drop from high | -58.45% | -10.84% |
| Avg time to new high | 66 days | 12 days |
| Max time to new high | 2807 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.63B
Marketcap category
Small-cap
Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Employees
539
Website
Investor relations
-
SEC filings
CEO
Jacqualyn A. Fouse
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page